Immune checkpoint inhibitors (ICIs), including antibodies directed against programmed cell death protein 1 (PD-1) or its ligand PD-L1, can reinstate dysregulated T-cell antitumor functions, thereby mediating the destruction of cancer cells (1). Here, PDCD1 is linked to cancer.